WhenCharles Dotter first described a metal coil that could hold the artery open after angioplasty, this was the birth of the concept of a coronary-artery stent. However,
it took 24 more years before could be used on the ischemic heart patients. Nowadays most patients routinely undergoing angioplasty have stents inserted as part of the interventional
procedure. The popularity of stents is based on the recognition that stenting results in an immediately improved angiographic outcome.
goal is to develop a new generation of Drug Eluting Stent that will retard
or stop restenosis, prevent platelet aggregation and adhesion, reduce
vascular inflammation, promote rapid endothelial cell attachment and function
within the lumen of the vessel and stent (a process called endothelialization)
and finally promote the release of VGEF which stimulates new blood vessels
formations (neoangiogenesis). The
development of ALP-S1 is based on its pharmaceutical features to promote
new blood-vessel generation in the heart
muscle. ALP-S1 has shown very promising
results, with excellent reendothelialization and anti-proliferation characteristics in
our in-vitro studies. We are currently conducting animal trials and plan
to have human trials in 2009.